At Janssen Immunology, our vision is a world free from immune and inflammatory diseases. To achieve this, we will translate internal and external science to deliver products that treat, cure and prevent immune-mediated diseases.
About Janssen Immunology
The Immunology Therapeutic Area (TA) of Janssen Research & Development, LLC, has redefined the standard of care in immunology over the past two decades. Through the work of our dedicated team of scientists and drug developers, the TA has propelled Janssen to a leadership position with cutting-edge treatments that address the needs of millions of patients living with autoimmune and inflammatory diseases.
We have been working for more than 20 years in the discovery, development and commercialization of monoclonal antibodies. We offered the first anti-tumor necrosis factor (TNF) antibody, leading a class of new medicines that have changed the way chronic conditions in gastroenterology, rheumatology and dermatology are treated. Today, biologic medicines have been used to treat millions of patients worldwide across a broad spectrum of inflammatory diseases, targeting the underlying drivers of disease—not just the symptoms.
Janssen Research & Development, LLC, is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Join our Immunology Talent Community for updates from the organization and information about new opportunities on our team.